A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2018
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biosensors Europe
- 21 Nov 2017 Status changed from not yet recruiting to recruiting.
- 24 Aug 2017 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.
- 24 Aug 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.